Ensartinib Hydrochloride Drug Due Diligence Report 2026

This Ensartinib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ensartinib Hydrochloride can convert its Small molecule drug profile and ALK x ROS1 x c-Met biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ensartinib Hydrochloride (query alias: ensartinib)
Modality / target	Small molecule drug; ALK x ROS1 x c-Met; ALK inhibitors, ROS1 inhibitors, c-Met inhibitors
Highest global status	Approved
Originator	Xcovery, Inc.
Active developers	Betta Pharmaceuticals Co., Ltd., Xcovery Holding, Inc.

The MCP disease footprint includes ALK positive Non-Small Cell Lung Cancer, Non-small cell lung cancer stage IIIB, Brain metastases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2500115167	Phase 4	Recruiting	137	Event-free survival period
ChiCTR2500113689	Phase 4	Pending	20	Pathological complete response rate (pCR)
NCT07448116	Phase 1/2	Recruiting	164	Dose-Limiting Toxicity (DLT) in Phase I

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

LBA66 - Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB ALK-positive (ALK+) non-small cell lung cancer (NSCLC) after complete tumor resection: The phase III randomized ELEVATE trial

Phase 3; n=274; evaluation: Positive. Reported fields: DFS(2-year) = 53.5 % ; DFS(2-year) = 86.4 %

Neoadjuvant Ensartinib for ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Real-World Study

Not Applicable; n=9; evaluation: Positive. Reported fields: AE = 77.8 %

关于恩沙替尼术后辅助适应症临床研究进展的公告

临床3期; n=not disclosed; evaluation: 积极. Reported fields: 主要终点 = 具有显著统计学意义和重要临床获益达到; 主要终点 = 具有显著统计学意义和重要临床获益达到

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ensartinib Hydrochloride addresses ALK positive Non-Small Cell Lung Cancer, Non-small cell lung cancer stage IIIB, Brain metastases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-04-17	贝达药业控股子公司Xcovery与美国Eversana公司达成恩沙替尼商业化合作	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “ALK mutations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutation”. The milestone feed surfaced a patent-application signal described as “ALK fusion genes and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO